Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.
Viktor A Adalsteinsson, Gavin Ha, Samuel S Freeman...
https://pubmed.ncbi.nlm.nih.gov/29109393/Actively Recruiting
Led by University College Hospital, Ibadan · Updated on 2026-05-07
42
Participants Needed
4
Research Sites
178 weeks
Total Duration
Researchers are studying triple negative breast cancer TNBC, an aggressive type of breast cancer that affects more Black women and younger age groups. This cancer lacks targeted treatments, so chemotherapy remains the main systemic therapy, though resistance often develops quickly. The study aims to evaluate the response rate to a standard chemotherapy regimen and explore if blood levels of microRNA and circulating tumor DNA can indicate treatment failure early in Nigerian women with TNBC. Participants will receive a sequence of chemotherapy drugs Epirubicin and Cyclophosphamide every three weeks for four cycles, followed by Paclitaxel and Carboplatin every three weeks for four cycles. Blood samples will be collected before, during, and after treatment to measure microRNA and tumor DNA levels. Tumor response will be assessed by ultrasound using RECIST criteria, and treatment side effects will be graded using CTCAE guidelines. Quality of life will be monitored with the EORTC questionnaire. During the study, patients will undergo clinical evaluations, imaging, blood tests, and quality of life assessments. The main outcomes include the proportion of patients achieving complete response after chemotherapy and the incidence of treatment-related side effects, monitored up to five years. Secondary measures include disease-free survival at 2, 5, and 10 years, and changes in quality of life. Total participation may last up to 10 years for long-term monitoring of outcomes and side effects.
CONDITIONS
MicroRNA Profiles in Triple Negative Breast Cancer
T
Tonyin Aniagwu
A
Abiodun Oni
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University College Hospital, Ibadan
Lead Sponsor
Lagos State University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 4 to 6 months
Participants receive chemotherapy with Epirubicin and Cyclophosphamide every three weeks for four cycles, followed by Paclitaxel and Carboplatin every three weeks for four cycles.
8 chemotherapy visits (every three weeks)
Duration - Up to 5 years
Participants are monitored for treatment response, side effects, quality of life, and disease status up to 5 years after treatment completion.
Periodic follow-up visits over 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Viktor A Adalsteinsson, Gavin Ha, Samuel S Freeman...
https://pubmed.ncbi.nlm.nih.gov/29109393/S Aebi, T Davidson, G Gruber...
https://pubmed.ncbi.nlm.nih.gov/21908498/Manfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas...
https://pubmed.ncbi.nlm.nih.gov/22193884/Davide Mauri, Nicholas Pavlidis, John P A Ioannidis
https://pubmed.ncbi.nlm.nih.gov/15687361/University College Hospital, Ibadan
Lead Sponsor
Lagos State University
Collaborating Sponsor